Review



s100a8 9  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems s100a8 9
    <t>Increased</t> <t>S100A8/9</t> expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.
    S100a8 9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/Recombinant+Mouse+S100A8+Protein%2C+CF/pmc13098576-222-9-12
    Average 93 stars, based on 16 article reviews
    s100a8 9 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis"

    Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

    Journal: JID Innovations

    doi: 10.1016/j.xjidi.2026.100470

    Increased S100A8/9 expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.
    Figure Legend Snippet: Increased S100A8/9 expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.

    Techniques Used: Expressing, Immunohistochemical staining, Control, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

    S100A8/9 directly activates small-diameter, nociceptive DRG sensory neurons. ( a ) Representative fluorescent images of cultured DRG sensory neurons isolated from Pirt GCaMP3/+ mice before and after S100A8/9 (100 ng/ml) application. Arrows point to sensory neurons showing increased GCaMP3 fluorescence levels after S100A8/9 application. (b) Histogram showing size distribution of S100A8/9-responsive neurons. (c–e) Representative traces of DRG neurons evoked by indicated chemicals, including S100A8/9 (100 ng/ml), S100A8 (100 ng/ml), S100A9 (100 ng/ml), capsaicin (1 μM), and KCl (75 mM) in a calcium imaging assay. All S100A8/9-sensitive neurons responded to capsaicin and KCl. The majority of S100A8- and S100A9-responsive neurons also responded to S100A8/9. The three different colors (Red, Green, and Blue) represent individual cells in C-E. (f) TAK-242 inhibited S100A8/9-induced calcium responses in sensory neurons. (n = 3 for both groups P = .018, Welch’s t -test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid; DRG, dorsal root ganglia.
    Figure Legend Snippet: S100A8/9 directly activates small-diameter, nociceptive DRG sensory neurons. ( a ) Representative fluorescent images of cultured DRG sensory neurons isolated from Pirt GCaMP3/+ mice before and after S100A8/9 (100 ng/ml) application. Arrows point to sensory neurons showing increased GCaMP3 fluorescence levels after S100A8/9 application. (b) Histogram showing size distribution of S100A8/9-responsive neurons. (c–e) Representative traces of DRG neurons evoked by indicated chemicals, including S100A8/9 (100 ng/ml), S100A8 (100 ng/ml), S100A9 (100 ng/ml), capsaicin (1 μM), and KCl (75 mM) in a calcium imaging assay. All S100A8/9-sensitive neurons responded to capsaicin and KCl. The majority of S100A8- and S100A9-responsive neurons also responded to S100A8/9. The three different colors (Red, Green, and Blue) represent individual cells in C-E. (f) TAK-242 inhibited S100A8/9-induced calcium responses in sensory neurons. (n = 3 for both groups P = .018, Welch’s t -test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid; DRG, dorsal root ganglia.

    Techniques Used: Cell Culture, Isolation, Fluorescence, Imaging

    S100A8/9 potentiate histamine-induced itch. ( a ) Subcutaneous injection of S100A8/9 (20 μg/ml) into the nape of the neck of wild-type mice does not induce scratching behavior. (n = 7 for both groups, P = .97, Welch’s t test). (b) Co-injection of S100A8/9 increased histamine (20 mM)-induced scratching behavior. (n = 11 for both groups, P = .038, Welch’s t test). Data are reported as mean ± SD.
    Figure Legend Snippet: S100A8/9 potentiate histamine-induced itch. ( a ) Subcutaneous injection of S100A8/9 (20 μg/ml) into the nape of the neck of wild-type mice does not induce scratching behavior. (n = 7 for both groups, P = .97, Welch’s t test). (b) Co-injection of S100A8/9 increased histamine (20 mM)-induced scratching behavior. (n = 11 for both groups, P = .038, Welch’s t test). Data are reported as mean ± SD.

    Techniques Used: Injection

    Related Articles

    Concentration Assay:

    Article Title: Impact of atopic dermatitis on renal dysfunction: insights from patient data and animal models
    Article Snippet: .. Serum samples were collected from AD-like mice, and the concentration of S100A8/9 was measured using a DuoSet ELISA kit (R&D Systems, Minneapolis, MN). ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Impact of atopic dermatitis on renal dysfunction: insights from patient data and animal models
    Article Snippet: .. Serum samples were collected from AD-like mice, and the concentration of S100A8/9 was measured using a DuoSet ELISA kit (R&D Systems, Minneapolis, MN). ..

    Article Title: The accessory type III secretion system effectors collectively shape intestinal inflammatory infection outcomes.
    Article Snippet: .. The concentrations of LCN2/NGAL and S100A8 was determined using DuoSet mouse Lipocalin-2 and S100A8 ELISA (R&D systems; Table S4) according to the manufacturer’s recommendations. ..

    Article Title: Neutrophil-derived exosomal S100A8 aggravates lung injury in sepsis by inducing pyroptosis.
    Article Snippet: Acute lung injury (ALI) is a common and life-threatening complication in patients with sepsis, with proinflammatory cell pyroptosis playing a crucial role in the associated organ damage.. In this study, we aimed to identify potential therapeutic targets.. Utilizing the GEO database (GSE232753), we analyzed the differentially expressed genes in the peripheral blood of healthy individuals and sepsis patients, identifying the significantly upregulated gene S100A8.

    Article Title: The accessory type III secretion system effectors collectively shape intestinal inflammatory infection outcomes
    Article Snippet: .. The concentrations of LCN2/NGAL and S100A8 was determined using DuoSet mouse Lipocalin-2 and S100A8 ELISA (R&D systems; Table S4) according to the manufacturer’s recommendations. ..

    Article Title: Methods of treating anemia in myelodysplastic syndromes
    Article Snippet: .. S100A8 in human samples was quantified using Human S100A8 DuoSet ELISA (DY4570, R&D Systems). .. Concentration of lineage-associated cytokines in cell culture supernatants of polarized T cells were quantified using a custom-made ProCarta Plex assay (Thermo Fisher Scientific) acquired on a Luminex platform.

    Article Title: Radiotherapy plus a self-gelation powder encapsulating tRF5-GlyGCC inhibitor potentiates natural kill cell immunity to prevent hepatocellular carcinoma recurrence.
    Article Snippet: The concentrations of S100A8, S100A9, IL-6, and ITGBL1 in the supernatants of tumor cells or HCC tissues were measured through Enzyme-linked immuno sorbent assay (ELISA) following the instructions provided by the manufacturer. .. The ELISA kits for S100A8, S100A9, and IL-6 were purchased from RD systems, and the ITGBL1 ELISA kit was purchased from BYabscience. ..

    Bioprocessing:

    Article Title: Dynamics of Th1/Th17 responses and antimicrobial pathways in leprosy skin lesions
    Article Snippet: .. Monoclonal antibodies (10 μg/mL) against human S100A7 (Thermo Fisher Scientific, catalog MA5-16199, clone 47c1068), S100A8 (R&D Systems, catalog MAB4570, clone 749916), CCL19 (Thermo Fisher Scientific, catalog MA5-23833, clone 54909), CCL17 (LSBio, catalog LS-C198166, clone 1F11), and CD68 (2 μg/mL) (Dako, catalog M087629-2, clone PG-M1) were used. ..

    Article Title: Dynamics of Th1/Th17 responses and antimicrobial pathways in leprosy skin lesions
    Article Snippet: .. Monoclonal antibodies (10μg/ml) for human S100A7 (ThermoFisher scientific, cat n°MA5-16199, clone 47c1068), S100A8 (R&D Systems, cat n°MAB4570, clone 749916), CCL19 (ThermoFisher scientific, cat n°MA5-23833, clone 54909), CCL17 (LSBio, cat n°LS-C198166, clone 1F11) and CD68 (2μg/ml) (Dako, cat n°M087629-2, clone PG-M1) were used. ..



    Similar Products

    95
    MedChemExpress s100a8 a9 inhibitor paquinimod
    Baseline Characteristics of Healthy Controls (HCs), Patients Without Sepsis-Related Liver Injury (SRLI), or Patients Without Sepsis-Related Liver Injury (Non-SRLI)
    S100a8 A9 Inhibitor Paquinimod, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/Paquinimod/pmc13484606-104-15-18
    Average 95 stars, based on 1 article reviews
    s100a8 a9 inhibitor paquinimod - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    99
    Biotium calgranulin b / mrp-8/-14 / mac 387 / s100a8/a9 / macrophage ag(mac387)
    Baseline Characteristics of Healthy Controls (HCs), Patients Without Sepsis-Related Liver Injury (SRLI), or Patients Without Sepsis-Related Liver Injury (Non-SRLI)
    Calgranulin B / Mrp 8/ 14 / Mac 387 / S100a8/A9 / Macrophage Ag(mac387), supplied by Biotium, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/Calgranulin+B+%2F+MRP-8%2F-14+%2F+MAC+387+%2F+S100A8%2FA9+%2F+Macrophage+Ag(MAC387)/custom%40bnc040035-100%4042070672
    Average 99 stars, based on 1 article reviews
    calgranulin b / mrp-8/-14 / mac 387 / s100a8/a9 / macrophage ag(mac387) - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    94
    MedChemExpress recombinant rat s100a8 protein
    Baseline Characteristics of Healthy Controls (HCs), Patients Without Sepsis-Related Liver Injury (SRLI), or Patients Without Sepsis-Related Liver Injury (Non-SRLI)
    Recombinant Rat S100a8 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/S100A8%2C+Rat/pm42349222-69-0-12
    Average 94 stars, based on 1 article reviews
    recombinant rat s100a8 protein - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    86
    Jackson Laboratory s100a8 cre
    Description (A) and characterization of endothelial cell ( ec PD-L1 −/− ) (B, D) or neutrophil ( pmn PD-L1 −/− ) (C, E) restricted constitutive PD-L1 gene-deficient mice. Taconic Knockout Repository [mouse TF0103 (MGI:1926446); Taconic Biosciences Inc., Germantown, NY], CD274/PD-L1 conditional knockout mouse. PD-L1 gene exons 1 to 4 are shown as green boxes and loxP sites flanking exon 2 are depicted as red triangles (A) . Homozygous PD-L1 flox/flox were subsequently crossed to either VE-Cadherin‐Cre (B6.FVB-Tg[Cdh5-cre]7Mlia/J; Strain #:006137; RRID: IMSR_JAX:006137) or <t>the</t> <t>S100a8-Cre</t> (B6.Cg-Tg[S100a8-cre,-EGFP]1IIw/J; Strain #:021614; RRID: IMSR_JAX:021614) mice, obtained from Jackson Labs, to produce either mice homozygous for both the flox PD-L1 and specific cell-lineage Cre promoter genes or mice that were heterozygous for one or both genes that served as “Controls”. Gating strategy and typical flow cytogram/dot plot of select cell-lineage restricted PD-L1 expression [either CD31 and PD-L1 (B) or Ly6G and PD-L1 (C) ] for various breeding outcomes from respective Cre-Lox matings for PD-L1 flox/flox animals with VE-Cadherin‐Cre (B) or PD-L1 flox/flox animals with S100a8-Cre (C) . Summary data for the change in percentage PD-L1 + endothelial cells (CD31 + ) (D) and percentage PD-L1 + neutrophils (Ly6G + ) (E) . A dotted line is provided to indicate median frequency of non-specific antibody binding typically detected using gating strategy during analysis, which was 2.75% ± 1.77% CD31 + PD-L1 + (D) and 2.29 ± 0.50% Ly6G + PD-L1 + (E) , respectively. The presence of a significant difference between groups was established at * p < 0.05 with a Mann–Whittney U test.
    S100a8 Cre, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/cre+mice+s100a8/pmc13268903-39-8-12
    Average 86 stars, based on 1 article reviews
    s100a8 cre - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Biocompare bioassaytm s100a8 elisa kit
    Description (A) and characterization of endothelial cell ( ec PD-L1 −/− ) (B, D) or neutrophil ( pmn PD-L1 −/− ) (C, E) restricted constitutive PD-L1 gene-deficient mice. Taconic Knockout Repository [mouse TF0103 (MGI:1926446); Taconic Biosciences Inc., Germantown, NY], CD274/PD-L1 conditional knockout mouse. PD-L1 gene exons 1 to 4 are shown as green boxes and loxP sites flanking exon 2 are depicted as red triangles (A) . Homozygous PD-L1 flox/flox were subsequently crossed to either VE-Cadherin‐Cre (B6.FVB-Tg[Cdh5-cre]7Mlia/J; Strain #:006137; RRID: IMSR_JAX:006137) or <t>the</t> <t>S100a8-Cre</t> (B6.Cg-Tg[S100a8-cre,-EGFP]1IIw/J; Strain #:021614; RRID: IMSR_JAX:021614) mice, obtained from Jackson Labs, to produce either mice homozygous for both the flox PD-L1 and specific cell-lineage Cre promoter genes or mice that were heterozygous for one or both genes that served as “Controls”. Gating strategy and typical flow cytogram/dot plot of select cell-lineage restricted PD-L1 expression [either CD31 and PD-L1 (B) or Ly6G and PD-L1 (C) ] for various breeding outcomes from respective Cre-Lox matings for PD-L1 flox/flox animals with VE-Cadherin‐Cre (B) or PD-L1 flox/flox animals with S100a8-Cre (C) . Summary data for the change in percentage PD-L1 + endothelial cells (CD31 + ) (D) and percentage PD-L1 + neutrophils (Ly6G + ) (E) . A dotted line is provided to indicate median frequency of non-specific antibody binding typically detected using gating strategy during analysis, which was 2.75% ± 1.77% CD31 + PD-L1 + (D) and 2.29 ± 0.50% Ly6G + PD-L1 + (E) , respectively. The presence of a significant difference between groups was established at * p < 0.05 with a Mann–Whittney U test.
    Bioassaytm S100a8 Elisa Kit, supplied by Biocompare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/bioassaytm+elisa+kit+s100a8/pm42076409-346-25-38
    Average 86 stars, based on 1 article reviews
    bioassaytm s100a8 elisa kit - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    93
    R&D Systems s100a8 9
    <t>Increased</t> <t>S100A8/9</t> expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.
    S100a8 9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/Recombinant+Mouse+S100A8+Protein%2C+CF/pmc13098576-222-9-12
    Average 93 stars, based on 1 article reviews
    s100a8 9 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    R&D Systems immunohistochemistry
    <t>Increased</t> <t>S100A8/9</t> expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.
    Immunohistochemistry, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/Human+S100A8+Antibody/pmc13098576-187-8-13
    Average 93 stars, based on 1 article reviews
    immunohistochemistry - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    R&D Systems anti s100a8 antibody
    Increased <t>S100A8/9</t> expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with <t>anti-S100A8/9</t> antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.
    Anti S100a8 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/Human+S100A8+Antibody/pmc13098576-187-10-13
    Average 93 stars, based on 1 article reviews
    anti s100a8 antibody - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    94
    Cyagen Biosciences s100a8 cre
    Increased <t>S100A8/9</t> expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with <t>anti-S100A8/9</t> antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.
    S100a8 Cre, supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/S100a8/pmc12993022-46-1-13
    Average 94 stars, based on 1 article reviews
    s100a8 cre - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    95
    R&D Systems elisa kit
    Increased <t>S100A8/9</t> expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with <t>anti-S100A8/9</t> antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.
    Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a8/Human+S100A8%2FS100A9+Heterodimer+Quantikine+ELISA+Kit/pmc13098576-207-17-19
    Average 95 stars, based on 1 article reviews
    elisa kit - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    Image Search Results


    Baseline Characteristics of Healthy Controls (HCs), Patients Without Sepsis-Related Liver Injury (SRLI), or Patients Without Sepsis-Related Liver Injury (Non-SRLI)

    Journal: Journal of Inflammation Research

    Article Title: S100A8/A9 Inhibition Reduces Neutrophil Extracellular Trap Formation and Mitigates Sepsis-Related Liver Injury

    doi: 10.2147/JIR.S609689

    Figure Lengend Snippet: Baseline Characteristics of Healthy Controls (HCs), Patients Without Sepsis-Related Liver Injury (SRLI), or Patients Without Sepsis-Related Liver Injury (Non-SRLI)

    Article Snippet: To investigate the effect of S100A8/A9 on SRLI, wild-type mice were intraperitoneally injected with the S100A8/A9 inhibitor paquinimod (MedChemExpress, Monmouth Junction, NJ, USA) at a dose of 10 mg/kg 24 h before CLP or sham surgery.

    Techniques:

    Receiver Operating Characteristic (ROC) Curve Analysis Results of  S100A8/A9  on Patients Without Sepsis-Related Liver Injury (SRLI)

    Journal: Journal of Inflammation Research

    Article Title: S100A8/A9 Inhibition Reduces Neutrophil Extracellular Trap Formation and Mitigates Sepsis-Related Liver Injury

    doi: 10.2147/JIR.S609689

    Figure Lengend Snippet: Receiver Operating Characteristic (ROC) Curve Analysis Results of S100A8/A9 on Patients Without Sepsis-Related Liver Injury (SRLI)

    Article Snippet: To investigate the effect of S100A8/A9 on SRLI, wild-type mice were intraperitoneally injected with the S100A8/A9 inhibitor paquinimod (MedChemExpress, Monmouth Junction, NJ, USA) at a dose of 10 mg/kg 24 h before CLP or sham surgery.

    Techniques:

    Description (A) and characterization of endothelial cell ( ec PD-L1 −/− ) (B, D) or neutrophil ( pmn PD-L1 −/− ) (C, E) restricted constitutive PD-L1 gene-deficient mice. Taconic Knockout Repository [mouse TF0103 (MGI:1926446); Taconic Biosciences Inc., Germantown, NY], CD274/PD-L1 conditional knockout mouse. PD-L1 gene exons 1 to 4 are shown as green boxes and loxP sites flanking exon 2 are depicted as red triangles (A) . Homozygous PD-L1 flox/flox were subsequently crossed to either VE-Cadherin‐Cre (B6.FVB-Tg[Cdh5-cre]7Mlia/J; Strain #:006137; RRID: IMSR_JAX:006137) or the S100a8-Cre (B6.Cg-Tg[S100a8-cre,-EGFP]1IIw/J; Strain #:021614; RRID: IMSR_JAX:021614) mice, obtained from Jackson Labs, to produce either mice homozygous for both the flox PD-L1 and specific cell-lineage Cre promoter genes or mice that were heterozygous for one or both genes that served as “Controls”. Gating strategy and typical flow cytogram/dot plot of select cell-lineage restricted PD-L1 expression [either CD31 and PD-L1 (B) or Ly6G and PD-L1 (C) ] for various breeding outcomes from respective Cre-Lox matings for PD-L1 flox/flox animals with VE-Cadherin‐Cre (B) or PD-L1 flox/flox animals with S100a8-Cre (C) . Summary data for the change in percentage PD-L1 + endothelial cells (CD31 + ) (D) and percentage PD-L1 + neutrophils (Ly6G + ) (E) . A dotted line is provided to indicate median frequency of non-specific antibody binding typically detected using gating strategy during analysis, which was 2.75% ± 1.77% CD31 + PD-L1 + (D) and 2.29 ± 0.50% Ly6G + PD-L1 + (E) , respectively. The presence of a significant difference between groups was established at * p < 0.05 with a Mann–Whittney U test.

    Journal: Frontiers in Immunology

    Article Title: Endothelial cell, but not neutrophil, programmed cell death receptor-ligand 1 loss has a morbid impact on experimental murine shock/sepsis-induced lung injury

    doi: 10.3389/fimmu.2026.1816915

    Figure Lengend Snippet: Description (A) and characterization of endothelial cell ( ec PD-L1 −/− ) (B, D) or neutrophil ( pmn PD-L1 −/− ) (C, E) restricted constitutive PD-L1 gene-deficient mice. Taconic Knockout Repository [mouse TF0103 (MGI:1926446); Taconic Biosciences Inc., Germantown, NY], CD274/PD-L1 conditional knockout mouse. PD-L1 gene exons 1 to 4 are shown as green boxes and loxP sites flanking exon 2 are depicted as red triangles (A) . Homozygous PD-L1 flox/flox were subsequently crossed to either VE-Cadherin‐Cre (B6.FVB-Tg[Cdh5-cre]7Mlia/J; Strain #:006137; RRID: IMSR_JAX:006137) or the S100a8-Cre (B6.Cg-Tg[S100a8-cre,-EGFP]1IIw/J; Strain #:021614; RRID: IMSR_JAX:021614) mice, obtained from Jackson Labs, to produce either mice homozygous for both the flox PD-L1 and specific cell-lineage Cre promoter genes or mice that were heterozygous for one or both genes that served as “Controls”. Gating strategy and typical flow cytogram/dot plot of select cell-lineage restricted PD-L1 expression [either CD31 and PD-L1 (B) or Ly6G and PD-L1 (C) ] for various breeding outcomes from respective Cre-Lox matings for PD-L1 flox/flox animals with VE-Cadherin‐Cre (B) or PD-L1 flox/flox animals with S100a8-Cre (C) . Summary data for the change in percentage PD-L1 + endothelial cells (CD31 + ) (D) and percentage PD-L1 + neutrophils (Ly6G + ) (E) . A dotted line is provided to indicate median frequency of non-specific antibody binding typically detected using gating strategy during analysis, which was 2.75% ± 1.77% CD31 + PD-L1 + (D) and 2.29 ± 0.50% Ly6G + PD-L1 + (E) , respectively. The presence of a significant difference between groups was established at * p < 0.05 with a Mann–Whittney U test.

    Article Snippet: The VE-Cadherin‐Cre (Strain #:006137; RRID: IMSR_JAX:006137) and the S100a8-Cre (Strain #:021614; RRID: IMSR_JAX:021614) breeder mouse strains were also obtained from The Jackson Laboratory (see ).

    Techniques: Knock-Out, Expressing, Binding Assay

    Increased S100A8/9 expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.

    Journal: JID Innovations

    Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

    doi: 10.1016/j.xjidi.2026.100470

    Figure Lengend Snippet: Increased S100A8/9 expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.

    Article Snippet: Chemicals used are listed as follows: S100A8, S100A9, and S100A8/9 (100 ng/ml, R&D Systems, 9877-S8, 2065-S9, 8916-S8), Bam8-22 (1 μM, custom synthesized by Genscript), and capsaicin (Sigma M2028, 1 μM).

    Techniques: Expressing, Immunohistochemical staining, Control, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

    S100A8/9 directly activates small-diameter, nociceptive DRG sensory neurons. ( a ) Representative fluorescent images of cultured DRG sensory neurons isolated from Pirt GCaMP3/+ mice before and after S100A8/9 (100 ng/ml) application. Arrows point to sensory neurons showing increased GCaMP3 fluorescence levels after S100A8/9 application. (b) Histogram showing size distribution of S100A8/9-responsive neurons. (c–e) Representative traces of DRG neurons evoked by indicated chemicals, including S100A8/9 (100 ng/ml), S100A8 (100 ng/ml), S100A9 (100 ng/ml), capsaicin (1 μM), and KCl (75 mM) in a calcium imaging assay. All S100A8/9-sensitive neurons responded to capsaicin and KCl. The majority of S100A8- and S100A9-responsive neurons also responded to S100A8/9. The three different colors (Red, Green, and Blue) represent individual cells in C-E. (f) TAK-242 inhibited S100A8/9-induced calcium responses in sensory neurons. (n = 3 for both groups P = .018, Welch’s t -test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid; DRG, dorsal root ganglia.

    Journal: JID Innovations

    Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

    doi: 10.1016/j.xjidi.2026.100470

    Figure Lengend Snippet: S100A8/9 directly activates small-diameter, nociceptive DRG sensory neurons. ( a ) Representative fluorescent images of cultured DRG sensory neurons isolated from Pirt GCaMP3/+ mice before and after S100A8/9 (100 ng/ml) application. Arrows point to sensory neurons showing increased GCaMP3 fluorescence levels after S100A8/9 application. (b) Histogram showing size distribution of S100A8/9-responsive neurons. (c–e) Representative traces of DRG neurons evoked by indicated chemicals, including S100A8/9 (100 ng/ml), S100A8 (100 ng/ml), S100A9 (100 ng/ml), capsaicin (1 μM), and KCl (75 mM) in a calcium imaging assay. All S100A8/9-sensitive neurons responded to capsaicin and KCl. The majority of S100A8- and S100A9-responsive neurons also responded to S100A8/9. The three different colors (Red, Green, and Blue) represent individual cells in C-E. (f) TAK-242 inhibited S100A8/9-induced calcium responses in sensory neurons. (n = 3 for both groups P = .018, Welch’s t -test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid; DRG, dorsal root ganglia.

    Article Snippet: Chemicals used are listed as follows: S100A8, S100A9, and S100A8/9 (100 ng/ml, R&D Systems, 9877-S8, 2065-S9, 8916-S8), Bam8-22 (1 μM, custom synthesized by Genscript), and capsaicin (Sigma M2028, 1 μM).

    Techniques: Cell Culture, Isolation, Fluorescence, Imaging

    S100A8/9 potentiate histamine-induced itch. ( a ) Subcutaneous injection of S100A8/9 (20 μg/ml) into the nape of the neck of wild-type mice does not induce scratching behavior. (n = 7 for both groups, P = .97, Welch’s t test). (b) Co-injection of S100A8/9 increased histamine (20 mM)-induced scratching behavior. (n = 11 for both groups, P = .038, Welch’s t test). Data are reported as mean ± SD.

    Journal: JID Innovations

    Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

    doi: 10.1016/j.xjidi.2026.100470

    Figure Lengend Snippet: S100A8/9 potentiate histamine-induced itch. ( a ) Subcutaneous injection of S100A8/9 (20 μg/ml) into the nape of the neck of wild-type mice does not induce scratching behavior. (n = 7 for both groups, P = .97, Welch’s t test). (b) Co-injection of S100A8/9 increased histamine (20 mM)-induced scratching behavior. (n = 11 for both groups, P = .038, Welch’s t test). Data are reported as mean ± SD.

    Article Snippet: Chemicals used are listed as follows: S100A8, S100A9, and S100A8/9 (100 ng/ml, R&D Systems, 9877-S8, 2065-S9, 8916-S8), Bam8-22 (1 μM, custom synthesized by Genscript), and capsaicin (Sigma M2028, 1 μM).

    Techniques: Injection

    Increased S100A8/9 expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.

    Journal: JID Innovations

    Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

    doi: 10.1016/j.xjidi.2026.100470

    Figure Lengend Snippet: Increased S100A8/9 expression in the skin and serum of patients with BP and AD. ( a ) Immunohistochemical analysis with anti-S100A8/9 antibody showing the expression of S100A8/9 in keratinocytes and infiltrating inflammatory cells of lesional skin of patients with BP and AD. S100A8/9 expression was not observed in the healthy skin. Scale bar: 100 μm. (b) Quantification of the expression level of S100A8/9. (control, n = 2; BP, n = 5; AD n = 2). Inter-patient heterogeneity of the expression level of S100A8/9 was observed in the BP skin samples, and representative images of both low and high S100A8/9 expression were shown in A. (c) ELISA analysis showing increased S100A8/9 concentrations in the serum of patients with BP. (control, n = 8; BP, n = 16; P = .0087, Mann-Whitney test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid.

    Article Snippet: Five-micrometer paraffin sections were collected and stained for immunohistochemistry with anti-S100A8 antibody (1:8000, R&D Systems, MAB4570).

    Techniques: Expressing, Immunohistochemical staining, Control, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

    S100A8/9 directly activates small-diameter, nociceptive DRG sensory neurons. ( a ) Representative fluorescent images of cultured DRG sensory neurons isolated from Pirt GCaMP3/+ mice before and after S100A8/9 (100 ng/ml) application. Arrows point to sensory neurons showing increased GCaMP3 fluorescence levels after S100A8/9 application. (b) Histogram showing size distribution of S100A8/9-responsive neurons. (c–e) Representative traces of DRG neurons evoked by indicated chemicals, including S100A8/9 (100 ng/ml), S100A8 (100 ng/ml), S100A9 (100 ng/ml), capsaicin (1 μM), and KCl (75 mM) in a calcium imaging assay. All S100A8/9-sensitive neurons responded to capsaicin and KCl. The majority of S100A8- and S100A9-responsive neurons also responded to S100A8/9. The three different colors (Red, Green, and Blue) represent individual cells in C-E. (f) TAK-242 inhibited S100A8/9-induced calcium responses in sensory neurons. (n = 3 for both groups P = .018, Welch’s t -test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid; DRG, dorsal root ganglia.

    Journal: JID Innovations

    Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

    doi: 10.1016/j.xjidi.2026.100470

    Figure Lengend Snippet: S100A8/9 directly activates small-diameter, nociceptive DRG sensory neurons. ( a ) Representative fluorescent images of cultured DRG sensory neurons isolated from Pirt GCaMP3/+ mice before and after S100A8/9 (100 ng/ml) application. Arrows point to sensory neurons showing increased GCaMP3 fluorescence levels after S100A8/9 application. (b) Histogram showing size distribution of S100A8/9-responsive neurons. (c–e) Representative traces of DRG neurons evoked by indicated chemicals, including S100A8/9 (100 ng/ml), S100A8 (100 ng/ml), S100A9 (100 ng/ml), capsaicin (1 μM), and KCl (75 mM) in a calcium imaging assay. All S100A8/9-sensitive neurons responded to capsaicin and KCl. The majority of S100A8- and S100A9-responsive neurons also responded to S100A8/9. The three different colors (Red, Green, and Blue) represent individual cells in C-E. (f) TAK-242 inhibited S100A8/9-induced calcium responses in sensory neurons. (n = 3 for both groups P = .018, Welch’s t -test). Data are reported as mean ± SD. AD, atopic dermatitis; BP, bullous pemphigoid; DRG, dorsal root ganglia.

    Article Snippet: Five-micrometer paraffin sections were collected and stained for immunohistochemistry with anti-S100A8 antibody (1:8000, R&D Systems, MAB4570).

    Techniques: Cell Culture, Isolation, Fluorescence, Imaging

    S100A8/9 potentiate histamine-induced itch. ( a ) Subcutaneous injection of S100A8/9 (20 μg/ml) into the nape of the neck of wild-type mice does not induce scratching behavior. (n = 7 for both groups, P = .97, Welch’s t test). (b) Co-injection of S100A8/9 increased histamine (20 mM)-induced scratching behavior. (n = 11 for both groups, P = .038, Welch’s t test). Data are reported as mean ± SD.

    Journal: JID Innovations

    Article Title: A neuroimmune axis linking S100A8/9 to itch sensitization in both bullous pemphigoid and atopic dermatitis

    doi: 10.1016/j.xjidi.2026.100470

    Figure Lengend Snippet: S100A8/9 potentiate histamine-induced itch. ( a ) Subcutaneous injection of S100A8/9 (20 μg/ml) into the nape of the neck of wild-type mice does not induce scratching behavior. (n = 7 for both groups, P = .97, Welch’s t test). (b) Co-injection of S100A8/9 increased histamine (20 mM)-induced scratching behavior. (n = 11 for both groups, P = .038, Welch’s t test). Data are reported as mean ± SD.

    Article Snippet: Five-micrometer paraffin sections were collected and stained for immunohistochemistry with anti-S100A8 antibody (1:8000, R&D Systems, MAB4570).

    Techniques: Injection